Amino Acid Metabolism Disorders Treatment Market Size is anticipated to register substantial growth between 2022 and 2028. Different types of such disorders include maple syrup urine disease, phenylketonuria (PKU), and others. Amino acids constitute the building blocks that combine together for the formation of proteins. If a person has one of these disorders, this might lead to trouble in breaking down particular amino acids. These problems result in a buildup of harmful substances in the human body, leading to serious and sometimes life-threatening health issues.
As the prevalence of these issues increases, so do the treatment options, which will push the industry growth in the years ahead.
On the basis of product, the amino acid metabolism disorders treatment market is set to record appreciable proceeds from carglumic acid segment up to 2028. This rise is mainly attributed to an increase in approvals for various carglumic acid-based drugs. For instance, in January 2021, the U.S. Food and Drug Administration gave approval for the deployment of carglumic acid tablets (200 mg) for the purpose of treating acute hyperammonemia related to methylmalonic acidemia and propionic acidemia.
The approval enables Recordati Rare Diseases to proceed with the treatment as an adjunctive therapy to standard of care for both adult and pediatric patients.
By sales channel, the hospital pharmacies segment is expected to register a considerable revenue in the overall amino acid metabolism disorders treatment market share over the forecast period. These pharmacies typically stock an extensive number of specialized devices and provide medications to the hospital inpatients. The segment growth is impelled by the surging burden of genetic disorders, in turn boosting industry expansion through the coming years.
Considering the regional perspective, North America amino acid metabolism disorders treatment market is estimated to depict lucrative growth by 2028 owing to an upsurge in research and development activities across the region.
For instance, in March 2021, a research team led by the White-McGarrah Lab identified a novel pathophysiologic impact for a class of BCAA (branched-chain amino acid) metabolites called BCKA (branched-chain keto acids) in the heart. The study demonstrated that acute exposure of the heart to BCKA levels found in obese, but not lean individuals, leads to the rapid alteration of the phosphoproteomic landscape of the heart, in turn activating the synthesis of cardiac protein.
Leading players in the amino acid metabolism disorders treatment industry include Civentichem, Pfizer, Merck KGaA, AMINO GmbH, GlaxoSmithKline plc, and others. These companies are focusing on mergers, acquisitions, product developments, collaborations, and partnerships for maintaining their foothold across the market.
Citing an instance, in September 2021, Pfizer Inc., and OPKO Health Inc., announced the extension of the review period by the U.S. FDA for the Biologics License Application for somatrogon for the treatment of GHD (growth hormone deficiency) in pediatric patients.
The COVID-19 pandemic led to an increase in studies regarding the effect of the virus on human metabolism. For instance, a recent research examined the main changes in serum metabolites associated with mild and severe SARS-CoV-2 patients by means of gas chromatography combined with mass spectrometry. The modifications in the metabolic profiles were related to an altered amino acid catabolism in hypoxic conditions. Such studies are expected to enhance awareness regarding numerous amino acid metabolism disorder symptoms, further propelling the development of various treatments and procedures.
The amino acid metabolism disorders treatment market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028 for the following segments:
Market, by Indication
Market, by Product
Market, by Distribution Channel
The above information is provided for the following regions and countries: